Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer

Nature Reviews Urology

Volumn 11, Issue 4, 2014, Pages 220-230

  Zargar, Homayoun ^a   Aning, Jonathan ^b   Ischia, Joseph ^c   So, Alan ^d   Black, Peter ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c AUSTIN HEALTH   (Australia)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYTOTOXIC AGENT; MITOMYCIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHEMOHYPERTHERMIA THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HYPERTHERMIC THERAPY; MAINTENANCE THERAPY; MULTIDRUG RESISTANCE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; HUMANS; MITOMYCIN; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 84901191738     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.52     Document Type: Article

References (90)

1. Tolley, D. A. et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J. Urol. 155, 1233-1238 (1996).
2. Sylvester, R. J., Oosterlinck, W. & van der Meijden, A. P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta-T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. 171, 2186-2190, quiz 2435 (2004).
3. Dalton, J. T., Wientjes, M. G., Badalament, R. A., Drago, J. R. & Au, J. L. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res. 51, 5144-5152 (1991).
4. Maeda, T., Kikuchi, E., Matsumoto, K., Miyajima, A. & Oya, M. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. J. Urol. 185, 802-806 (2011).
5. Ersoy, H. et al. Single early instillation of mitomycin C and urinary alkalinization in low-risk non: muscle: invasive bladder cancer: a preliminary study. Drug Des. Devel. Ther. 7, 1-6 (2013).
6. Wientjes, M. G., Badalament, R. A. & Au, J. L. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother. Pharmacol. 32, 255-262 (1993). (Pubitemid 23172082)
7. Au, J. L. et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J. Natl Cancer Inst. 93, 597-604 (2001).
8. van der Heijden, A. G., Verhaegh, G., Jansen, C. F., Schalken, J. A. & Witjes, J. A. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J. Urol. 173, 1375-1380 (2005).
9. Paroni, R. et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br. J. Clin. Pharmacol. 52, 273-278 (2001). (Pubitemid 33796224)
10. Synergo® - For the treatment of Non-muscle Invasive Bladder Cancer. The technology [online], http://www.synergo-medical.com/-!the: synergo: system-en/cloi (2014).
11. Colombo, R. et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol. 21, 4270-4276 (2003).
12. Colombo, R., Salonia, A., Leib, Z., PavoneMacaluso, M. & Engelstein, D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycinC alone as adjuvant treatment for nonmuscleinvasive bladder cancer (NMIBC). BJU Int. 107, 912-918 (2011).
13. Lammers, R. J. et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of nonmuscleinvasive bladder cancer: a systematic review. Eur. Urol. 60, 81-93 (2011).
14. ISRCTN Register. HYMN: a trial comparing hyperthermia and mitomycin chemotherapy with a second BCG treatment, or other standard treatment, for bladder cancer that has come back [online], http://www.controlled-trials.com/ ISRCTN85785327/ (2013).
15. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/
16. NCT00384891term=NCT00384891&rank=1 (2010).
17. Di Stasi, S. M. et al. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res. 59, 4912-4918 (1999). (Pubitemid 29472896)
18. Di Stasi, S. M. et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol. 170, 777-782 (2003).
19. Di Stasi, S. M. et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 7, 43-51 (2006).
20. Kaasinen, E. et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur. Urol. 43, 637-645 (2003).
21. Rintala, E., Jauhiainen, K., Kaasinen, E., Nurmi, M. & Alfthan, O. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J. Urol. 156, 56-59; discussion 59-60 (1996).
22. Di Stasi, S. M. et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 12, 871-879 (2011).
23. Colombo, R. et al. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J. Urol. 155, 1227-1232 (1996).
24. Colombo, R. et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent nonmuscleinvasive bladder cancer: preliminary results of a randomised phase 2 study. Eur. Urol. 62, 797-802 (2012).
25. Dominguez-Escrig, J. L., Kelly, J. D., Neal, D. E., King, S. M. & Davies, B. R. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin. Cancer Res. 10, 4874-4884 (2004). (Pubitemid 38955542)
26. Pritchett, T. R., Wang, J. K. & Jones, P. A. Mesenchymal-epithelial interactions between normal and transformed human bladder cells. Cancer Res. 49, 2750-2754 (1989). (Pubitemid 19143410)
27. Bohle, A. & Bock, P. R. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63, 682-686; discussion 686-687 (2004).
28. Malmstrom, P. U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for nonmuscleinvasive bladder cancer. Eur. Urol. 56, 247-256 (2009).
29. Dalbagni, G. Is intravesical bacillus Calmette-Guerin better than mitomycin for intermediate-risk bladder cancer? Eur. Urol. 56, 257-258; discussion 258-259 (2009).
30. Oddens, J. et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur. Urol. 63, 462-472 (2013).
31. Lamm, D. L. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124-1129 (2000).
32. Krege, S., Giani, G., Meyer, R., Otto, T. & Rubben, H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. J. Urol. 156, 962-966 (1996).
33. Malmstrom, P. U. et al. 5year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J. Urol. 161, 1124-1127 (1999).
34. Gardmark, T., Jahnson, S., Wahlquist, R., Wijkstrom, H. & Malmstrom, P. U. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycinC and bacillus Calmette-Guerin in patients with high-risk bladder cancer. BJU Int. 99, 817-820 (2007). (Pubitemid 46439578)
35. Friedrich, M. G., Pichlmeier, U., Schwaibold, H., Conrad, S. & Huland, H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guerin (BCG) in patients with nonmuscleinvasive bladder carcinoma. Eur. Urol. 52, 1123-1129 (2007).
36. Bouffioux, C. et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J. Urol. 153, 934-941 (1995).
37. Badalato, G. M., Hruby, G., Razmjoo, M. & McKiernan, J. M. Maximizing intravesical therapy options: is there an advantage to the administration of perioperative mitomycin C prior to an induction course of BCG? Can. J. Urol. 18, 5890-5895 (2011).
38. Rajala, P. et al. Cytostatic effect of different strains of Bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha. Urol. Res. 20, 215-217 (1992).
39. Matsushima, M. et al. Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model. Oncol. Lett. 2, 13-19 (2011).
40. Witjes, J. A., Caris, C. T., Mungan, N. A., Debruyne, F. M. & Witjes, W. P. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J. Urol. 160, 1668-1671; discussion 1671-1672 (1998).
41. Oosterlinck, W. et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guerin and with bacillus Calmette-Guerin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur. Urol. 59, 438-446 (2011).
42. Rintala, E. et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J. Urol. 154, 2050-2053 (1995).
43. Delto, J. C., Kobayashi, T., Benson, M., McKiernan, J. & Abate-Shen, C. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression. Oncotarget 4, 269-276 (2013).
44. Maymi, J. L., Saltsgaver, N. & O'Donnell, M. A. Intravesical sequential gemcitabine- mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer [abstract 840]. J. Urol. 175 (Suppl.), 271 (2006).
45. Lightfoot, A. J. et al. Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer. Urol. Oncol. 32,.e15-e19 (2014).
46. Breyer, B. N., Whitson, J. M., Carroll, P. R. & Konety, B. R. Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer. Urol. Oncol. 28, 510-514 (2010).
47. Chen, C. H. et al. A cocktail regimen of intravesical mitomycinC, doxorubicin, and cisplatin (MDP) for nonmuscleinvasive bladder cancer. Urol. Oncol. 30, 421-427 (2012).
48. Mullerad, M. et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J. Urol. 741-746 (2005).
49. Deb, A. A. et al. Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro. J. Urol. 186, 2426-2433 (2011).
50. Villalona-Calero, M. A. et al. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 9, 3303-3311 (2003).
51. Xin, Y. et al. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J. Urol. 174, 322-327 (2005).
52. Lamont, F. R. et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br. J. Cancer 104, 75-82 (2011).
53. Gust, K. M. et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol. Cancer Ther. 12, 1245-1254 (2013).
54. Hartl, F. U. & Hayer-Hartl, M. Converging concepts of protein folding in vitro and in vivo. Nat. Struct. Mol. Biol. 16, 574-581 (2009).
55. Calderwood, S. K., Khaleque, M. A., Sawyer, D. B. & Ciocca, D. R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem. Sci. 31, 164-172 (2006). (Pubitemid 43361923)
56. Parsell, D. A. & Lindquist, S. The function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu. Rev. Genet. 27, 437-496 (1993). (Pubitemid 24011359)
57. Zoubeidi, A. & Gleave, M. Small heat shock proteins in cancer therapy and prognosis. Int. J. Biochem. Cell Biol. 44, 1646-1656 (2012).
58. Lebret, T. et al. Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 98, 970-977 (2003). (Pubitemid 37022097)
59. Kassem, H., Sangar, V., Cowan, R., Clarke, N. & Margison, G. P. A potential role of heat shock proteins and nicotinamide N: methyl transferase in predicting response to radiation in bladder cancer. Int. J. Cancer 101, 454-460 (2002).
60. Kamada, M. et al. HSP27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 6, 299-308 (2007). (Pubitemid 46206694)
61. Richards, E., Begum, T. & Masters, J. Thermotolerance and sensitivity of human cancer cells to cisplatin and doxorubicin. Int. J. Oncol. 8, 1265-1271 (1996). (Pubitemid 26178574)
62. Behnsawy, H. M., Miyake, H., Kusuda, Y. & Fujisawa, M. Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells. Urol. Oncol. 31, 843-848 (2013).
63. He, L. F. et al. Enhanced sensitivity to mitomycin C by abating heat shock protein 70 expression in human bladder cancer cell line of BIU: 87. Chin. Med. J. (Engl.) 118, 1965-1972 (2005).
64. Hadaschik, B. A. et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein: 27 inhibit the growth of non: muscle: invasive bladder cancer. BJU Int. 102, 610-616 (2008).
65. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00959868term=NCT00959868&rank=1 (2012).
66. Endicott, J. A. & Ling, V. The biochemistry of P: glycoprotein: mediated multidrug resistance. Annu. Rev. Biochem. 58, 137-171 (1989).
67. Schuldes, H., Dolderer, J. H., Schoch, C., Bickeboller, R. & Woodcock, B. G. Cytostatic sensitivity and MDR in bladder carcinoma cells: implications for tumor therapy. Int. J. Clin. Pharmacol. Ther. 38, 204-208 (2000). (Pubitemid 30193616)
68. Tasaki, Y. et al. Reversal by a dihydropyridine derivative of non: P: glycoprotein-mediated multidrug resistance in etoposide-resistant human prostatic cancer cell line. J. Urol. 154, 1210-1216 (1995).
69. Shinohara, N., Liebert, M., Wedemeyer, G., Chang, J. H. & Grossman, H. B. Evaluation of multiple drug resistance in human bladder cancer cell lines. J. Urol. 150, 505-509 (1993).
70. Park, J. et al. P: glycoprotein expression in bladder cancer. J. Urol. 151, 43-46 (1994).
71. Naito, S. et al. Correlation between the expression of P: glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Eur. Urol. 22, 158-162 (1992).
72. Hasegawa, S. et al. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br. J. Cancer 71, 907-913 (1995).
73. Nakagawa, M. et al. Clinical significance of multi-drug resistance associated protein and Pglycoprotein in patients with bladder cancer. J. Urol. 157, 1260-1264; discussion 1264-1265 (1997).
74. Pu, Y. S. et al. Expression of MDR1 gene in transitional cell carcinoma and its correlation with chemotherapy response. J. Urol. 156, 271-275 (1996).
75. Gontero, P. et al. Ex vivo chemosensitivity to mitomycin C in bladder cancer and its relationship with P: glycoprotein and apoptotic factors. Anticancer Res. 22, 4073-4080 (2002). (Pubitemid 36134436)
76. Frisch, S. M. & Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124, 619-626 (1994).
77. Frisch, S. M. & Ruoslahti, E. Integrins and anoikis. Curr. Opin. Cell Biol. 9, 701-706 (1997). (Pubitemid 27424927)
78. Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662-668 (1999). (Pubitemid 29289430)
79. Aoudjit, F. & Vuori, K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20, 4995-5004 (2001). (Pubitemid 32769789)
80. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658-1667 (1999). (Pubitemid 29102494)
81. Pan, C. W. et al. Cell adhesion to fibronectin induces mitomycin C resistance in bladder cancer cells. BJU Int. 104, 1774-1779 (2009).
82. Zhang, C. J. et al. Engagement of integrin-1 induces resistance of bladder cancer cells to mitomycin: C. Urology 79, 638-643 (2012).
83. Tannock, I. F., Lee, C. M., Tunggal, J. K., Cowan, D. S. & Egorin, M. J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. 8, 878-884 (2002). (Pubitemid 34742121)
84. Burgues, J. P. et al. A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids. Eur. Urol. 51, 962-969; discussion 969-970 (2007).
85. Gazzaniga, P. et al. A chemosensitivity test to individualize intravesical treatment for non: muscle: invasive bladder cancer. BJU Int. 104, 184-188 (2009).
86. Lee, J. K. et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl Acad. Sci. USA 104, 13086-13091 (2007).
87. Smith, S. C., Baras, A. S., Lee, J. K. & Theodorescu, D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 70, 1753-1758 (2010).
88. Smith, S. C. et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia 13, 72-80 (2011).
89. Shen, K. et al. A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. PLoS ONE 7, e49529 (2012).
90. Ferriss, J. S. et al. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS ONE 7, e30550 (2012).